Diabetes PubMed

No difference between the patients visiting the center with fulminant type 1 diabetes and those with non-fulminant type 1 diabetes was observed in the development of microangiopathy complications.

Nevertheless, metabolic syndrome remains to be an important clinical entity for overcoming the diabetic macrovascular complications, because it provides basis not only for the incidence of type 2 diabetes but also for rational and comprehensive management of multiple cardiovascular risks in diabetic patients.

Adequate control of diabetes mellitus might postpone or perhaps even prevent the microvascular disease.

Our data suggest that attempts to improve glycemic control reduce the incidence of macrovascular events both in type 1 and type 2 DM.

Therefore, to prevent micro- and macrovascular complications, like PVD, in type-1 and type-2 diabetes, intensive therapy, targeting glycemia and all other modifiable cardiovascular risk factors, should be initiated as soon after diagnosis as possible and maintained in a safe way throughout life.

In diabetic microangiopathy, hyperglycemia induces biochemical and molecular changes in microvascular cells that ultimately progress to retinal, renal, and neural complications and extends to other complications, including advanced periodontal disease.